Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShort-Term Debt repayments
Ratios

BioNexus Gene Lab (BGLC) Receivables Refunds (2019 - 2025)

BioNexus Gene Lab's Receivables Refunds history spans 7 years, with the latest figure at $103640.0 for Q3 2025.

  • For Q3 2025, Receivables Refunds rose 368.28% year-over-year to $103640.0; the TTM value through Sep 2025 reached $103640.0, up 368.28%, while the annual FY2024 figure was $84167.0, 46.15% up from the prior year.
  • Receivables Refunds for Q3 2025 was $103640.0 at BioNexus Gene Lab, up from $101471.0 in the prior quarter.
  • Across five years, Receivables Refunds topped out at $103640.0 in Q3 2025 and bottomed at $1767.0 in Q1 2022.
  • The 5-year median for Receivables Refunds is $31551.0 (2022), against an average of $41287.3.
  • The largest YoY upside for Receivables Refunds was 1641.44% in 2023 against a maximum downside of 92.72% in 2023.
  • A 5-year view of Receivables Refunds shows it stood at $2727.0 in 2021, then surged by 1056.99% to $31551.0 in 2022, then surged by 82.52% to $57588.0 in 2023, then soared by 46.15% to $84167.0 in 2024, then grew by 23.14% to $103640.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Receivables Refunds are $103640.0 (Q3 2025), $101471.0 (Q2 2025), and $89937.0 (Q1 2025).